Free Trial

Liberty One Investment Management LLC Raises Position in Merck & Co., Inc. (NYSE:MRK)

Merck & Co., Inc. logo with Medical background

Liberty One Investment Management LLC grew its holdings in Merck & Co., Inc. (NYSE:MRK - Free Report) by 17.3% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 42,522 shares of the company's stock after buying an additional 6,275 shares during the period. Liberty One Investment Management LLC's holdings in Merck & Co., Inc. were worth $3,817,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. Stratos Investment Management LLC raised its position in shares of Merck & Co., Inc. by 147.4% in the first quarter. Stratos Investment Management LLC now owns 112,002 shares of the company's stock valued at $10,053,000 after buying an additional 66,737 shares during the last quarter. Navalign LLC increased its position in Merck & Co., Inc. by 3.8% during the first quarter. Navalign LLC now owns 14,118 shares of the company's stock worth $1,267,000 after purchasing an additional 516 shares during the last quarter. Investment Partners LTD. increased its position in Merck & Co., Inc. by 10.1% during the first quarter. Investment Partners LTD. now owns 5,189 shares of the company's stock worth $466,000 after purchasing an additional 477 shares during the last quarter. ARGA Investment Management LP acquired a new stake in Merck & Co., Inc. during the first quarter worth about $11,504,000. Finally, Bank Hapoalim BM increased its position in Merck & Co., Inc. by 31.6% during the first quarter. Bank Hapoalim BM now owns 26,754 shares of the company's stock worth $2,401,000 after purchasing an additional 6,420 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Citigroup restated a "neutral" rating and set a $84.00 price objective (down from $115.00) on shares of Merck & Co., Inc. in a research report on Wednesday, May 14th. Wall Street Zen cut shares of Merck & Co., Inc. from a "strong-buy" rating to a "buy" rating in a research report on Friday, April 25th. Guggenheim restated a "buy" rating and set a $115.00 price objective on shares of Merck & Co., Inc. in a research report on Thursday, April 17th. Finally, Cantor Fitzgerald lowered shares of Merck & Co., Inc. from an "overweight" rating to a "cautious" rating in a research note on Tuesday, May 20th. One analyst has rated the stock with a sell rating, twelve have issued a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $109.19.

Read Our Latest Stock Analysis on Merck & Co., Inc.

Insider Buying and Selling at Merck & Co., Inc.

In other news, SVP Dalton E. Smart III sold 4,262 shares of the business's stock in a transaction that occurred on Friday, April 25th. The shares were sold at an average price of $82.76, for a total transaction of $352,723.12. Following the completion of the sale, the senior vice president owned 7,778 shares in the company, valued at approximately $643,707.28. The trade was a 35.40% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.13% of the company's stock.

Merck & Co., Inc. Stock Up 2.9%

NYSE:MRK traded up $2.37 during mid-day trading on Wednesday, hitting $83.74. The stock had a trading volume of 18,390,570 shares, compared to its average volume of 13,368,539. The stock has a 50-day simple moving average of $79.09 and a two-hundred day simple moving average of $86.73. The company has a market capitalization of $210.27 billion, a PE ratio of 12.19, a PEG ratio of 0.84 and a beta of 0.39. Merck & Co., Inc. has a twelve month low of $73.31 and a twelve month high of $129.93. The company has a current ratio of 1.41, a quick ratio of 1.16 and a debt-to-equity ratio of 0.69.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The company reported $2.22 earnings per share for the quarter, topping the consensus estimate of $2.16 by $0.06. The business had revenue of $15.53 billion during the quarter, compared to the consensus estimate of $15.59 billion. Merck & Co., Inc. had a net margin of 27.27% and a return on equity of 43.23%. The company's revenue was down 1.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.07 EPS. On average, equities research analysts anticipate that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, July 8th. Stockholders of record on Monday, June 16th were given a dividend of $0.81 per share. The ex-dividend date of this dividend was Monday, June 16th. This represents a $3.24 annualized dividend and a dividend yield of 3.87%. Merck & Co., Inc.'s dividend payout ratio is presently 47.16%.

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Featured Stories

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Should You Invest $1,000 in Merck & Co., Inc. Right Now?

Before you consider Merck & Co., Inc., you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.

While Merck & Co., Inc. currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines